Modulating the tumor microenvironment

Dirk Jäger*

National Center for Tumor Diseases (NCT) Heidelberg, Germany

* Corresponding author, email: dirk.jaeger@nct-heidelberg.de

© 2018 Dirk Jäger; licensee Infinite Science Publishing

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Immunotherapy works in some patients, in most patients it does not. We have tumor entities that show low objective response rates like CRC or PDAC. We identified the immunosuppressive environment being the main mechanisms of resistance. Therefore strategies that target such suppressive mechanisms are being developed clinically. We currently evaluate CCR5 blockade in combination with checkpoint inhibition in MSS-CRC and PDAC.